240 results about "Antithrombotic" patented technology

The invention provides an anticoagulant coating for medical instruments, which can be used in the field of regenerative medical instruments. The prepared anticoagulant coating has short-term and long-term anticoagulant performance, and in addition, the thrombin responsive nanoparticles wrapped in the hydrogel coating can selectively release a factor Xa (FXa) inhibitor apixaban according to needs, so that thrombosis is inhibited in the middle stage of implantation. In-vitro and in-vivo experimental evidences show that after the material is implanted for a long time, an organized endodermis can be seen on the surface of the material, and the material has a special antithrombotic characteristic. The dynamic adjusting system has a multi-layer protection mechanism, and a new thought can be provided for designing the surface of a contact blood material adapting to environmental conditions.

The invention relates to ultra-small prussian blue nano-particles (T-USPB-C) carrying tirofian, a preparation method of the nano-particles and application of the nano-particles in preparation of drugs for reducing MVO and MIRI. According to the preparation method, the T-USPB-C is prepared by three steps. The T-USPB-C provided by the invention can carry tirofiban, and has catalase and superoxide dismutase simulated nano-enzyme activity. Moreover, the size of the nano-scale drug is required to reach a nano-scale size, and the drug can be efficiently cleared through kidney excretion, so that the potential long-term toxicity problem is minimized. The ultra-small prussian blue nanoparticle carrying the tirofian has an excellent active oxygen scavenging capability. Microvascular perfusion can be rapidly improved through the antithrombotic effect, then the protection effect is continuously achieved through the anti-oxidation and anti-inflammatory mechanism, and microvascular injury and MIRI are effectively prevented.

To provide: a method for producing an anti-thrombogenic material in which white turbidity is reduced; a method for producing a medical instrument coated with the anti-thrombogenic material produced by the method; and an anti-thrombogenic material in which white turbidity is reduced.SOLUTION: A method for producing an anti-thrombogenic material according to the present invention comprises a step of copolymerizing a specific alkyl (meth)acrylate, a silicone (meth)acrylate, and an alkoxy polyethylene glycol (meth)acrylate, wherein the silicone (meth)acrylate used here has a weight average molecular weight of 1450 or less.SELECTED DRAWING: None

The invention relates to the technical field of biological medicine, in particular to a targeting nanoparticle and a preparation method and application thereof. The targeted nano-particle designed and synthesized by the invention comprises a nano-liposome and low-molecular heparin entrapped in the nano-liposome, wherein the surface of the nano-liposome is modified with CREKA peptide. Wherein the CREKA peptide can target fibrinogen in thrombus and specifically recognize FN1 at the thrombus part, so that LMWH is delivered to the thrombus part in a targeted manner, the local antithrombotic effect is improved, meanwhile, the risks of extra bleeding and toxicity are reduced to the maximum extent, and the limitation of traditional LMWH is solved.

The invention belongs to the technical field of food or medicine, and particularly relates to a preparation method of nattokinase sustained-release microspheres, which comprises the following steps: mixing an emulsifier span-80 with liquid paraffin to obtain an oil phase; adding chitosan into an acetic acid solution to prepare a chitosan water solution as a water phase; dropwise adding the water phase into the oil phase to prepare W / O type emulsion, dropwise adding a cross-linking agent A into the emulsion to obtain chitosan microspheres, and taking a chitosan microsphere nattokinase solution and a cross-linking agent B to obtain nattokinase-chitosan core microspheres; mixing the nattokinase-chitosan core microsphere with a cortisol aptamer solution, and incubating to enable the aptamer to be combined on the surface of the nattokinase-chitosan core microsphere; and adding a casein-PEG copolymer solution and a cross-linking agent C into the microspheres to obtain the cortisol response type intelligent switch microspheres. The nattokinase release amount can be dynamically adjusted day and night, the circadian thrombus risk rhythm is matched, the anti-thrombus effect is remarkably improved, side effects are reduced, and the nattokinase can be widely applied to the fields of functional food and drugs.

The invention discloses an antibacterial and antithrombotic medical catheter and a preparation method thereof. According to the medical catheter, a hydrogel coating is prepared on the surface of the medical catheter, the hydrogel coating contains a three-layer structure, and the medical catheter has low swelling property and excellent mechanical property, stability, durability, platelet adhesion resistance, antibacterial property and biocompatibility. The preparation method disclosed by the invention is simple, efficient and environment-friendly; the dopamine layer provides strong adhesion performance, glucose oxidase entrapped in FDA provides longer-term antibacterial performance, and finally the carboxylic acid betaine zwitterionic coating is introduced to further enhance the antithrombotic performance of the hydrogel coating, so that the hydrogel coating medical catheter is produced. The invention provides a new strategy for the low-expansion amphiphilic ion hydrogel coating with antithrombotic and antibacterial properties in the field of biomedical materials, especially as a medical catheter, and the coating can be applied to biomedical equipment in contact with blood.

The invention discloses an application of an ester compound in preparation of an antithrombotic drug. The structural formula of the ester compound is as shown in the following formula: # imgabs0 #. The ester compound can reduce blood clot formation in thrombus tissues by inhibiting TF expression and improve thrombus-related pathological processes by regulating the level of inflammatory factors (such as TXB2 and 6-keto-PGF1 alpha), and is used for preparing antithrombotic drugs.

The invention belongs to the technical field of biomedical materials, and particularly relates to a poly-4-methyl-1-pentene (PMP) gas-blood exchange membrane for an extracorporeal membrane oxygenation (ECMO) system, which realizes a long-acting antithrombotic function through a bionic interface construction technology. The invention aims to provide a bionic antithrombotic PMP gas-blood exchange membrane based on zwitter-ion gradient grafting, and through material and process innovation, the following problems existing in a traditional ECMO gas-blood exchange membrane: an antithrombotic coating is easy to fall off, and the long-term effect is insufficient; the risk of blood injury caused by dependence on heparin or anticoagulants; and the surface modification process destroys the membrane pore structure and air permeability.

The invention relates to the technical field of traditional Chinese medicine health-care products, and particularly discloses an earthworm protein peptide composition for improving vascular embolism and a preparation method thereof.The earthworm protein peptide composition is prepared from, by weight, 28-34 parts of earthworm protein peptide, 20-26 parts of active pharmaceutical ingredients, 1-5 parts of ginkgo biloba extract, 12-15 parts of corn oligopeptide powder and 4-8 parts of auxiliary materials; lumbricus protein peptide, active pharmaceutical ingredients, ginkgo biloba extract and corn oligopeptide powder are used as raw materials, a solubilizing component is added in the preparation process, the solubilizing component is prepared by mixing functional extract, nattokinase and tween-80 according to a certain proportion, the functional extract is prepared by coating grape seed extract with hydroxypropyl-beta-cyclodextrin, and the solubilizing component is prepared by mixing the functional extract, the nattokinase and the tween-80 according to a certain proportion. Through the synergistic effect of the components, the antithrombotic effect of the earthworm protein peptide composition is synergistically enhanced.

The invention belongs to the technical field of microorganisms and biological medicines, and particularly relates to a postbiotic preparation for improving vascular elasticity and relieving hypertension and thrombus as well as a preparation method and application of the postbiotic preparation. Specifically, a strain of lactobacillus rhamnosus is obtained through screening, a postbiotic preparation is successfully developed based on the strain, and tests prove that the lactobacillus rhamnosus has the effects of reducing inflammatory response of vascular endothelium and reducing oxidative stress level so as to promote repair and regeneration of vascular endothelial cells, improve vascular elasticity and quickly improve hypertension; the anti-thrombus effect can be realized. Meanwhile, by optimizing the condition parameters of the preparation process of the metabolite preparation and combining anaerobic fermentation and aerobic fermentation on the lactobacillus rhamnosus, the advantage that metabolites are comprehensive and rich is achieved, and the metabolite preparation has good practical application value.

The invention discloses an anticoagulation endothelium slow release promoting coating and a preparation method thereof, and relates to the technical field of biomedical materials, the method comprises the following steps: soaking a substrate material in a guide layer solution prepared from dopamine, a silane coupling agent containing double bonds and an amino compound; immersing in an assembly layer solution prepared from a double-bond functionalized high-molecular compound and an endothelial active promoting substance, taking out, and carrying out photo-crosslinking curing; and immersing in a regulation and control layer solution prepared from a double-bond functionalized high-molecular compound and a zwitterionic monomer, and finally taking out for photo-crosslinking and curing to obtain the anti-coagulation endothelial sustained-release promoting coating. According to the method, efficient packaging and slow release of anticoagulation and endothelialization promoting active substances are achieved, and the prepared coating remarkably improves the performance of a blood contact instrument in the aspects of acute-stage thrombus formation resistance and long-acting endothelialization promotion after implantation.

The invention belongs to the field of surface function modification of medical instruments and biological materials, and particularly relates to a natural biological driven long-term stable anti-thrombus and endothelialization improved blood flow guiding device and a preparation method. The specific biological functional molecular layer provided by the invention can realize natural-like anticoagulation at the initial stage of implantation and natural biological driving endothelialization progress, so as to realize long-acting steady-state antithrombosis, and the specific biological functional molecular layer combines endothelial progenitor cells and endothelial cells, so that the endothelial progenitor cells and the endothelial cells are combined, and the endothelial progenitor cells and the endothelial cells are combined. The method realizes capture and differentiation of specific endothelial progenitor cells and adhesion, migration and proliferation of endothelial cells, improves effective re-endothelialization to the greatest extent, ensures natural biological characteristics of the endothelial progenitor cells, realizes natural remodeling of blood vessel inner wall tissues to achieve the purpose of stable growth and thrombosis resistance, is a new function idea which is difficult to realize by other schemes in the prior art, and has wide application prospects. The blood guiding device is a surface-improved blood guiding device which has nature-like anticoagulation and can drive endothelialization progress to obtain a long-acting steady state through natural biological property.

In one aspect, the invention provides compositions and methods for preventing, reducing, and / or treating a disease, disorder or condition associated with fibrin-induced activation of the complement system and the associated activation of the coagulation and / or contact systems comprising administering a therapeutic amount of a MASP-2 inhibitory antibody to a subject in need thereof. In some embodiments, the methods of the invention provide anticoagulation and / or antithrombosis and / or antithrombogenesis without affecting hemostasis. In one embodiment of this aspect of the invention, the compositions and methods are useful for treating a subject is suffering from, or at risk of developing, a disease, disorder or condition associated with complement-related inflammation, excessive coagulation or contact system activation initiated by fibrin or activated platelets.

The invention relates to a medical device for treating aneurysms, in particular a stent, including a compressible and expandable grid structure made up of grid elements. The grid structure has at least one closed cell ring which includes at most 12, in particular at most 10, in particular at most 8, in particular at most 6 cells directly adjacent to one another in a circumferential direction of the grid structure. The grid structure is provided at least in certain portions with a covering made of an electrospun fabric which has pores of irregular sizes. The covering includes over a surface area of 100 000 μm2 at least 10 pores which have a size of at least 15 μm2. The covering has a biocompatible, in particular antithrombogenic and / or endothelialization-promoting coating.

A series of sofalcone derivatives are provided.SOLUTION: A series of sofalcone derivatives provided by the present invention are, for example, compounds having a structure of formula (I), and have platelet aggregation inhibitory and antithrombotic effects. The sofalcone derivatives of the present invention are TxA2 receptor antagonists, have an inhibitory effect on platelet agglutination, and do not easily affect the hemostatic function. The present invention also provides a method for preparing the sofalcone derivative, and a method for using the sofalcone derivative for preventing or treating thrombotic diseases, or for inhibiting platelet aggregation.SELECTED DRAWING: None

Refreshing stylets, catheter systems, and methods thereof. The refreshing stylet can be configured to fit within a lumen of a catheter such as hemodialysis catheter. The refreshing stylet can include an elongated hollow body having a proximal portion coupled to a needleless connector, a distal portion ending in a distal tip, an interior surface, an exterior surface, and a side hole. The exterior surface can be coated with a sustained-release formulation including one or more anti-thrombotic agents. The sustained-release formulation can be configured to contact a luminal surface of the catheter and prevent thrombus formation thereon. The side hole can be configured to provide a locking solution to the lumen of the catheter for locking the catheter between uses.

This invention relates to the fields of molecular biology and biomedicine, disclosing plasma-active peptides with antithrombotic effects and their uses. The invention obtains various active peptides from plasma through screening and solid-phase synthesis, and confirms their biological activity through in vitro platelet aggregation experiments and in vivo arterial thrombosis model experiments. Results show that peptides 1957, 1960, and 1961 significantly inhibit collagen-induced platelet aggregation, exhibiting good antiplatelet activity; animal experiments show that peptides 1955, 1957, 1960, and 1961 significantly inhibit arterial thrombosis. These active peptides are derived from endogenous plasma components, belonging to natural antithrombotic substances, possessing good physiological compatibility and safety advantages, and reducing the risk of immunogenicity and adverse reactions. These peptides can exert antithrombotic effects without relying on traditional antiplatelet drugs, providing a new source of active molecules and treatment options for the prevention and treatment of thrombotic diseases.

The application discloses a nitrogen acetylated carbazole alkaloid, and the structure is selected from one of the following structures: The application discloses a nitrogen acetylated carbazole alkaloid produced by fermentation of streptomyces J1074, and provides a biosynthetic preparation method, which is more green and environmental protection, and cost reduction compared with a chemical synthesis method; the compound ATC-A provided by the application shows significant antithrombotic activity in a thrombotic zebrafish model, which may be related to down-regulation of gene expression related to platelet activation and blood coagulation cascade, and has important development prospect and clinical application value.

Novel binding molecules comprising humanized antibodies, fragments, variants, and derivatives thereof, as well as compositions, methods, and kits comprising the same, are described, wherein the binding molecules specifically bind to FX1 and FX1a. The binding molecules are capable of binding to the factor X1A2 domain and forming immune complexes, thereby disrupting the contact activation molecule complex without affecting the activity or activation of hemostatic factor XI. The binding molecules disclosed herein are suitable for safely inhibiting thrombosis and inflammation without impairing hemostasis. Thus, the binding molecules, compositions, methods, and kits provided herein are intended for treating diseases and conditions, particularly those associated with thrombosis and inflammation. In addition, polynucleotides encoding the binding molecules disclosed herein, vectors comprising the polynucleotides, and host cells for producing the polynucleotides are also provided.

Provided are a novel antithrombotic antibody targeting a blood coagulation factor FIXa-FVIIIa binding site and an application thereof.SOLUTION: The present invention provides a novel antithrombotic antibody, which targets FIXa and has unique properties, specifically targets the binding site of blood coagulation factors FIXa and FVIIIa, reduces the formation of FVIIIa-FIXa complex, blocks the conversion of FX to FXa, and exerts an antithrombotic effect. The antibody of the present invention has an appropriate antithrombotic performance and a large effective therapeutic concentration window, but does not increase the bleeding risk, which can achieve the need for moderate antithrombosis and effectively avoid the bleeding problem caused by excessive action in clinical applications. The present invention also discloses methods of screening for drugs that target the FIXa-FVIIIa binding site.SELECTED DRAWING: Figure 1A

The invention relates to a preparation method of an artificial blood vessel, the artificial blood vessel is composed of a porous support layer, a biodegradation layer and an antithrombotic layer, and the method comprises the following steps: soaking an expanded polytetrafluoroethylene substrate with silver nitrate doped polyvinyl pyrrolidone-poly-N-isopropylacrylamide to obtain the porous support layer; and then assembling a biodegradable material and an antithrombotic material as a biodegradable layer and an antithrombotic layer. The invention also relates to the artificial blood vessel prepared by the method.

The present application relates to the field of biomedicine technology, and in particular to the use of an antithrombotic small molecule compound BPTU (CAS No. 870544-59-5) as a colistin adjuvant for synergistic anti-Gram-negative bacteria, wherein the antithrombotic small molecule compound BPTU comprises a compound as shown in Formula I; the use of the antithrombotic small molecule compound BPTU as a colistin adjuvant for synergistic anti-Gram-negative bacteria, BPTU and colistin have a synergistic antibacterial effect on Gram-negative bacteria, the outer membrane of Gram-negative bacteria can act as a drug barrier, and colistin has membrane-breaking activity, and colistin breaks the barrier effect of the cell membrane to assist BPTU in entering the cell to exert its antibacterial activity. Therefore, the combined use of the antithrombotic small molecule compound BPTU and colistin has broad application prospects in the treatment of Gram-negative bacteria.

Novel methods, compositions and kits for using lymphatic targeting anti-thrombosis (LTAT) molecules are provided herein. The LTAT molecules can be used to treat or prevent lymphatic thrombosis resulting particularly from infection or inflammation in the intestine.

The invention belongs to the technical field of medicines, and discloses application of pantethine in preparation of medicines for preventing and / or treating thrombotic diseases or medicines for inhibiting platelet activation or regulating vascular endothelial cell functions. In-vivo and in-vitro experiments prove that pantethine can remarkably relieve thrombus load in a mouse thrombus model, down-regulate expression of vWF (von Willebrand Factor), up-regulate expression of TFPI (Tissue Factor Path Inhibitor) and TH BD (Thromboregulatory Protein), and antagonize platelet adhesion, aggregation and activation induced by a platelet activator. The action mechanism is closely related to inhibition of reactive oxygen species (ROS) generation and NF-kappa B signal channel activation, and improvement of endothelial cell functions. It can be known from the invention that pantethine plays an antithrombotic role from multiple aspects, and is suitable for preparation of antithrombotic drugs for prevention or treatment. The invention provides a new drug choice for prevention and treatment of thrombotic diseases.

The invention relates to a blood contact material and a preparation method thereof. The preparation method of the blood contact material comprises the following steps that the anticoagulant layer is covalently connected to the surface of the base material in an atom transfer radical polymerization mode, the tail end of a polymer in the anticoagulant layer is provided with an initiator group, and the anticoagulant layer comprises one or more of a hydrophilic anticoagulant layer and a heparin anticoagulant layer; and reacting the initiator group with the substance with the NO catalytic release function to prepare the blood contact material. According to the preparation method, the stability of the membrane layer can be improved while a relatively good antithrombotic effect is ensured.

Provided herein are novel methods, compositions, and kits for targeting antithrombotic (LTAT) molecules using lymph. The LTAT molecule can be used for treating or preventing lymphatic thrombosis caused by infection or inflammation, in particular in the intestinal tract.

The invention discloses a traditional Chinese medicine composition for treating ischemic stroke and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from, by weight, 7-10 parts of salvia miltiorrhiza, 10-20 parts of astragalus membranaceus, 4-8 parts of ligusticum wallichii, 2-4 parts of scalded leeches, 2-4 parts of ground beetles, 2-4 parts of gastrodia elata, 4-8 parts of scorpions, 4-8 parts of polygala tenuifolia, 4-8 parts of acorus tatarinowii, 7-10 parts of red peony roots, 4-8 parts of carthamus tinctorius, 4-8 parts of angelica sinensis and 4-8 parts of peach kernels. According to the application, the compatibility structure is rigorous, the primary and secondary effects are clear, through multi-target intervention (antithrombosis, blood flow improvement and nerve protection), the advantages of'compound compatibility and overall adjustment 'of traditional Chinese medicine are embodied, and the aspects of movement, vision, language, cognitive functions and the like are remarkably improved.

The invention relates to the technical field of medical instruments, in particular to an internal and external fiber coated intravascular stent as well as a preparation method and application thereof. An inner fiber covering film and an outer fiber covering film with certain functions are respectively prepared by utilizing a coaxial electrostatic spinning technology, and the fiber covering film with a core-shell structure is prepared. The inner-layer fiber covering film takes a degradable polymer as a shell layer preparation raw material, so that the shell layer can be degraded within a certain time, thrombus and inflammation resistance is realized, and endothelialization is promoted; the anti-thrombus substance loaded on the shell layer is used for resisting acute thrombus, and can be used as a protective layer to ensure the activity of the substance for promoting vascular endothelial growth in the core layer, and the load can realize a slow release function, so that the loss of expected functions due to quick release of the load is avoided. The outer fiber membrane takes a degradable polymer as a shell layer preparation raw material, so that the shell layer can be degraded within a certain time, and tissue integration and infection resistance are promoted; antibacterial substances are loaded on the core layer and are slowly released under the wrapping of the shell layer.

The present invention relates to a pharmaceutical composition and a health functional food for the prevention or treatment of thrombosis containing an extract of *Barbarea orthoceras Ledeb*, and more specifically, to a pharmaceutical composition and a health functional food for the prevention or treatment / improvement of thrombosis through inhibition of blood coagulation containing, as an active ingredient, a hot water extract of the whole plant of *Barbarea orthoceras Ledeb* having potent thrombin inhibitory and blood coagulation factor inhibitory activities. The extract of *Barbarea orthoceras* (Ledeb) as an active ingredient in the pharmaceutical composition and health functional food for the prevention or treatment of thrombosis according to the present invention exhibits excellent antithrombotic activity through strong inhibition of thrombus-related enzymes such as thrombin and blood coagulation factors. At the same time, it does not exhibit any hemolytic activity against human red blood cells, has excellent thermal stability, and does not show loss of blood coagulation factor inhibitory effects or thrombus-related enzyme inhibitory effects even under acidic conditions of pH 2 and in plasma. Therefore, it is expected to be usable for the prevention and treatment of thrombosis, such as ischemic stroke and hemorrhagic stroke, through the improvement of blood circulation. Furthermore, since the active ingredient has the excellent effect of being processed into various forms such as extract, powder, pills, and tablets, allowing for formulation into a form suitable for regular consumption, this invention is highly useful for the pharmaceutical and food industries.

The invention discloses a 5 / 8 / 5 chitosan clostridium diterpenoid compound, a biosynthetic gene cluster and application of the biosynthetic gene cluster, and relates to the technical field of biological medicines. A 5 / 8 / 5 chitin type diterpenoid biosynthetic gene cluster Thm in trichoderma harzianum is identified through a genome mining system, chitin diterpenoid compounds with diversified structures are obtained by means of heterologous expression, the obtained compounds are subjected to anti-thrombotic activity comprehensive evaluation, and the result shows that the compounds 6 and 31 can obviously inhibit vascular thrombosis, the compound 6 has a remarkable inhibition effect on collagen-induced platelet aggregation, and the compound 31 has a better inhibition capability on thrombin-induced platelet activation. The compounds 6 and 31 show powerful antithrombotic effects in artery, vein and pulmonary artery thrombosis models, so that powerful technical support is provided for development of antithrombotic drugs.